Skip to main content
Premium Trial:

Request an Annual Quote

Mawi DNA Technologies Signs European Distribution Deal for Biosampling Products

NEW YORK — Mawi DNA Technologies said on Tuesday that it has signed a distribution agreement for its iSWAB biosampling products in certain European markets with Nucleus Biotech.

Under the terms of the deal, Heidelberg-based Nucleus will distribute the products in Germany, Austria, and Switzerland. Additional terms were not disclosed.

"Expanding our international presence is a key strategic component of Mawi's next phase of growth," Jerome David, VP of sales and marketing at Mawi, said in a statement. "We believe partnering with Nucleus Biotech will help us achieve this objective."

Mawi's iSWAB line of biospecimen collection devices include the company's flagship iSWAB-DNA for the collection of long-fragment double-stranded DNA from buccal cells, as well as iSWAB-Microbiome for microbial content in gut, rectal, vaginal, skin, oral, or soil samples. Mawi also offers iSWAB kits for the collection of RNA, blood, animal DNA, and protein.

In early 2019, Hayward, California-based Mawi signed a distribution agreement for its iSWAB products in the Middle East, Africa, and parts of Central and South Asia with Alliance Global.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.